FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313649218> ?p ?o ?g. }

• W4313649218 abstract "Abstract Lung cancer accounts for the most cancer-related deaths in the world. Our previous study suggested the improved survival of lung cancer patients, mainly female patients, with subsequent metachronous primary breast cancer. However, whether the survival advantages of the two primaries are associated with patients’ sex and the specific breast cancer is unclear. Whether male lung cancer patients with another primary may encounter the same survival advantage as female patients is also uncertain. The uncertainty hinders these patients from the potential benefit of lung cancer clinical trial. A total of 343 male lung adenocarcinoma patients with subsequent bladder papillary transitional cell carcinoma (LCBC), 1539 lung adenocarcinoma patients with prior bladder papillary transitional cell carcinoma (BCLC), 1181 lung adenocarcinoma patients with subsequent prostate adenocarcinoma (LCPC), 7426 lung adenocarcinoma patients with prior prostate adenocarcinoma (PCLC), and patients with single bladder/prostate/lung (SLC) cancer were identified from the Surveillance, Epidemiology, and End Results. Patients were classified into simultaneous two primary cancer (sTPC), metachronous two primary cancer 1 (mTPC1), or mTPC2 groups when interval time between two cancers was within 6 months, between 7 and 60 months, or over 60 months, respectively. Propensity matching score program was executed to match the two primary cancers with single primary. Cox regression and competing risk regression were performed to identify confounders associated with all-cause and cancer-specific survival, respectively. The major cancer-related and non-cancer-related death in the two primaries were lung cancer and heart disease, respectively. Median overall survival times since lung primary of LCBC and SLC were 97 and 17 months, respectively, and incidence of all-cause and cancer-specific death in LCBC since lung malignancy was significantly lower (Coef. − 1.24, 95% CI − 1.49 to 0.99; SHR 0.42, 95% CI 0.33–0.53). Among the categorized groups, prognosis values of sTPC and mTPC2 groups were not statically different from that of the matched single lung cancer, whereas increased overall survival time and decreased incidence of all-cause and cancer-specific death relative to the matched patients were observed in mTPC1 group (H.R 0.28, 95% CI 0.19–0.41; SHR 0.33, 95% CI 0.23–0.47). Similar prognosis of LCPC relative to SLC was also observed. Furthermore, a generally improved survival relative to SLC was observed in PCLC (median survival times of PCLC and SLC were 17 and 12 months, respectively; Coef. − 0.32, 95% CI − 0.43 to 0.22; SHR 0.77, 95% CI 0.69–0.85), whereas prognosis of BCLC was similar to the matched ones. These results hinted that survival of lung cancer patients might vary with prior cancer history. Further analysis among groups with the two primaries suggested that advanced bladder cancer was not associated with prognosis of patients with LCBC and BCLC. On the contrary, advanced prostate cancer was associated with all-cause and cancer-specific death in patients with PCLC but not in patients with LCPC. Compared with patients with single lung cancer, male lung cancer patients with subsequent bladder/prostate primary over 6 months experienced generally improved survival. These results were similar to our previous study regarding female lung cancer patients with another breast primary. On the contrary, male lung cancer patients with prior primary malignancy encountered varied prognosis: improved survival relative to single lung primary was observed in lung cancer with prior prostate cancer, whereas prognosis of lung cancer with prior bladder cancer was not different. Therefore, great attention was required to characterize prognosis of lung cancer patients with another primary in advance, which was essential to eliminate the potential bias when these patients were included into the clinical trials." @default.
• W4313649218 created "2023-01-07" @default.
• W4313649218 creator A5029225084 @default.
• W4313649218 creator A5035891055 @default.
• W4313649218 creator A5039012757 @default.
• W4313649218 creator A5056854347 @default.
• W4313649218 creator A5068361652 @default.
• W4313649218 date "2023-01-06" @default.
• W4313649218 modified "2023-10-01" @default.
• W4313649218 title "Prognosis of male lung cancer patients with urinary cancer: a study from a national population-based analysis" @default.
• W4313649218 cites W2006237276 @default.
• W4313649218 cites W2107949783 @default.
• W4313649218 cites W2144630462 @default.
• W4313649218 cites W2145601586 @default.
• W4313649218 cites W2160144478 @default.
• W4313649218 cites W2336130565 @default.
• W4313649218 cites W2418550904 @default.
• W4313649218 cites W2464386849 @default.
• W4313649218 cites W2588641161 @default.
• W4313649218 cites W2801133559 @default.
• W4313649218 cites W2991210534 @default.
• W4313649218 cites W2995087365 @default.
• W4313649218 cites W2998363033 @default.
• W4313649218 cites W3167472929 @default.
• W4313649218 cites W3185954239 @default.
• W4313649218 cites W3189679124 @default.
• W4313649218 doi "https://doi.org/10.1038/s41598-023-27566-8" @default.
• W4313649218 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36609573" @default.
• W4313649218 hasPublicationYear "2023" @default.
• W4313649218 type Work @default.
• W4313649218 citedByCount "0" @default.
• W4313649218 crossrefType "journal-article" @default.
• W4313649218 hasAuthorship W4313649218A5029225084 @default.
• W4313649218 hasAuthorship W4313649218A5035891055 @default.
• W4313649218 hasAuthorship W4313649218A5039012757 @default.
• W4313649218 hasAuthorship W4313649218A5056854347 @default.
• W4313649218 hasAuthorship W4313649218A5068361652 @default.
• W4313649218 hasBestOaLocation W43136492181 @default.
• W4313649218 hasConcept C121608353 @default.
• W4313649218 hasConcept C126322002 @default.
• W4313649218 hasConcept C143998085 @default.
• W4313649218 hasConcept C2776235491 @default.
• W4313649218 hasConcept C2776256026 @default.
• W4313649218 hasConcept C2780192828 @default.
• W4313649218 hasConcept C2781182431 @default.
• W4313649218 hasConcept C2908647359 @default.
• W4313649218 hasConcept C530470458 @default.
• W4313649218 hasConcept C71924100 @default.
• W4313649218 hasConcept C99454951 @default.
• W4313649218 hasConceptScore W4313649218C121608353 @default.
• W4313649218 hasConceptScore W4313649218C126322002 @default.
• W4313649218 hasConceptScore W4313649218C143998085 @default.
• W4313649218 hasConceptScore W4313649218C2776235491 @default.
• W4313649218 hasConceptScore W4313649218C2776256026 @default.
• W4313649218 hasConceptScore W4313649218C2780192828 @default.
• W4313649218 hasConceptScore W4313649218C2781182431 @default.
• W4313649218 hasConceptScore W4313649218C2908647359 @default.
• W4313649218 hasConceptScore W4313649218C530470458 @default.
• W4313649218 hasConceptScore W4313649218C71924100 @default.
• W4313649218 hasConceptScore W4313649218C99454951 @default.
• W4313649218 hasIssue "1" @default.
• W4313649218 hasLocation W43136492181 @default.
• W4313649218 hasLocation W43136492182 @default.
• W4313649218 hasLocation W43136492183 @default.
• W4313649218 hasOpenAccess W4313649218 @default.
• W4313649218 hasPrimaryLocation W43136492181 @default.
• W4313649218 hasRelatedWork W1967103478 @default.
• W4313649218 hasRelatedWork W1980245127 @default.
• W4313649218 hasRelatedWork W2032912323 @default.
• W4313649218 hasRelatedWork W2224319365 @default.
• W4313649218 hasRelatedWork W2372561159 @default.
• W4313649218 hasRelatedWork W2375344515 @default.
• W4313649218 hasRelatedWork W2390152934 @default.
• W4313649218 hasRelatedWork W2400504790 @default.
• W4313649218 hasRelatedWork W2403361534 @default.
• W4313649218 hasRelatedWork W3171615116 @default.
• W4313649218 hasVolume "13" @default.
• W4313649218 isParatext "false" @default.
• W4313649218 isRetracted "false" @default.
• W4313649218 workType "article" @default.